EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy

Mengchao An, Jiayao Yan, Baorui Liu, Qin Liu

Cancer Communications · 01.01.2026 · 46

DOI: 10.34133/cancomm.0023 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Communications, online erschienen am 10.04.2026. Verfasst von Mengchao An und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Comprehensive Cancer Center, Nanjing Drum Tower Hospital & Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Na…. Hauptthemen laut MEDLINE: Killer Cells, Natural, Neoplasms, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 278 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Jiangsu Provincial Medical Key Discipline, Nanjing Medical Key Laboratory of Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Solid tumors remain a formidable challenge in cancer therapy, often evading even the most advanced immunotherapies. Natural killer (NK) cells, cytotoxic innate lymphocytes capable of recognizing and eliminating tumor cells without prior antigen sensitization, have emerged as a compelling alternative to T cells in adoptive cell therapy. Compared to chimeric antigen receptor (CAR)-T cells, CAR-engineered NK cells offer distinct advantages, including a substantially reduced risk of graft-versus-host disease (GvHD) and cytokine release syndrome (CRS). These features enable the development of “off-the-shelf” allogeneic cell products with improved safety and accessibility. Early clinical studies of CAR-NK cells have demonstrated encouraging efficacy in hematological malignancies alongside an excellent safety profile, fueling enthusiasm to extend this approach to solid tumors. However, the efficacy of CAR-NK cell therapy against solid tumors is limited by multiple barriers, including the immunosuppressive tumor microenvironment, poor infiltration, and persistence of NK cells in tumor tissues, heterogeneity of tumor antigen expression leading to immune escape, and the potential for NK cell dysfunction or exhaustion in chronic tumor settings. To overcome these obstacles, innovative engineering strategies are being developed. Approaches include armoring CAR-NK cells to resist tumor-induced immunosuppression, enhancing their trafficking and persistence, designing multi-antigen-targeted receptors, and incorporating built-in safety switches. This review highlights CAR-NK antitumor mechanisms, examines key challenges in solid tumor applications, and discusses cutting-edge advances and combination strategies aimed at unlocking the full therapeutic potential of CAR-NK cells. By addressing these challenges, CAR-NK cell therapy could open a new frontier in solid tumor immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalNeoplasmsReceptors, Chimeric AntigenImmunotherapy, AdoptiveHumansAnimalsTumor MicroenvironmentImmunotherapy

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • The Comprehensive Cancer Center, Nanjing Drum Tower Hospital & Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.

Förderung

  • Jiangsu Provincial Medical Key Discipline
  • Nanjing Medical Key Laboratory of Oncology

Zitieren

APA

An, M., Yan, J., Liu, B., & Liu, Q. (2026). Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy. Cancer Communications, 46. https://doi.org/10.34133/cancomm.0023

Vancouver

An M, Yan J, Liu B, Liu Q. Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy. Cancer Communications. 2026;46. doi:10.34133/cancomm.0023

BibTeX
@article{An2026,
  author = {An, Mengchao and Yan, Jiayao and Liu, Baorui and Liu, Qin},
  title = {Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy},
  journal = {Cancer Communications},
  year = {2026},
  volume = {46},
  doi = {10.34133/cancomm.0023}
}
Kostenlos starten →